Sonomotion Announced FDA Clearance for its Break Wave™ Lithotripsy Device for Treatment of Kidney Stones
On January 21, 2026, SonoMotion, a venture-backed medical device company focused on developing non-invasive solutions for kidney stone treatment, announced that it had received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Break Wave lithotripsy device. Break Wave used low-pressure focused ultrasound to fragment kidney stones by generating standing stress waves within the stone under real-time ultrasound image guidance. The procedure was completely non-invasive and did not require anesthesia, enabling patients to drive themselves to and ...